Then came Felanorm and an opportunity to prove our claims. The marketplace for feline hyperthyroidism treatments was a sea of sameness. Clinical claims. Predictable imagery. Safe messaging. So we launched Norbrook’s new product based on a completely unexpected and disruptive point-of-view.

Every cat owner knows the truth: the pill pocket gets swallowed, the pill does not. The crushed tablet is sniffed out. The gel signals a sprint under the bed. Instead of speaking like a pharmaceutical brand, we spoke like someone who actually understood the struggle. We shifted the viewpoint to the cat and traded medical monotony for emotional truth:

“Small pill to you. Big deal to them.”

Suddenly veterinarians had a new reason to listen. Pet owners felt seen. And Felanorm didn’t have to shout to stand out. That’s how challenger brands win. Not by outspending. By outsmarting.

Our partnership has only accelerated from there. The mission to break through limitations remains the throughline as we now expand into Norbrook’s large animal division with the same creative bravery and the same refusal to blend in.

Our Partnership at a Glance:

Aligned internal stakeholders around a clear, ambitious brand identity
Shifted Norbrook’s market posture from manufacturer to value-added partner
Expanded into new marketing channels, increasing visibility and deepening audience connection
Extended messaging beyond veterinarians and distributors to include pet owners — creating stronger pull-through demand
Positioned Felanorm as a product of opportunity, which also made it more attractive for competitor acquisition